{
    "nct_id": "NCT05855694",
    "official_title": "Pilot Study of Photobiomodulation for Cancer-Related Cognitive Impairment",
    "inclusion_criteria": "* Adults ≥ 18 years\n* Previous diagnosis of stage I-III non-central nervous system solid tumor malignancy, Hodgkin, or Non-Hodgkin lymphoma\n* Completed cancer treatment (chemotherapy and/or radiation) more than 6 months ago but less than 5 years ago (Current concurrent endocrine therapy, anti-HER-2 therapy allowed, or other stable maintenance therapies (such as rituximab) will be allowed.\n* Self-reported cognitive complaints (score ≤ 54 on the Functional Assessment of Cancer Therapy-Cognition, Version 3, Perceived Cognitive Impairment subscale)\n* Written informed consent obtained from subject and ability for subject to comply with the requirements of the study.\n* Ability to read, write and understand either English OR Spanish.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Current pregnancy or nursing status\n* Current use of Photobiomodulation (PBM) (for any reason)\n* A lifetime history of any brain tumor or central nervous system metastasis\n* Previous use of intrathecal chemotherapy, chimeric antigen receptor treatment (CAR-T), or stem cell/marrow transplant\n* Known history of other neurological conditions involving impaired cognitive function (such as Alzheimer's Disease and related dementias, Parkinson's Disease, or Multiple Sclerosis).",
    "miscellaneous_criteria": ""
}